Conference Exhibitors

Bio-Diagnostics Ltd. is a UK-based diagnostics provider supporting NHS and private healthcare services for over 40 years.
Our core expertise sits within allergy diagnostics, where we support NHS departments with comprehensive Type I allergy testing that informs asthma and respiratory care pathways. By enabling accurate identification of allergic triggers, our services help clinicians optimise treatment decisions through accurate diagnosis resulting in improved patient outcomes.

Bio-Diagnostics is expanding its respiratory-focused offering through a new partnership with Bosch Healthcare. We are delighted to be representing the 'Vivatmo FeNO system' for UK and Ireland, which is clinically validated solution for measuring airway inflammation in asthma. The platform supports both clinic-based and home monitoring, enabling personalised, data-led asthma management while reducing the need for repeated face-to-face appointments.
FeNO home monitoring has demonstrated excellent usability, high patient adherence, and strong clinician confidence, supporting its integration into community and digitally enabled care models. This aligns closely with NHS priorities around prevention, remote monitoring, and proactive long-term condition management.

Bio-Diagnostics is keen to collaborate with NHS respiratory and allergy teams, ICS partners, and service providers to support pathway development, service transformation, and innovation across integrated care systems.

Orion Pharma (UK) Ltd. is a wholly owned subsidiary of Orion Corporation, a pharmaceutical company based in Finland. Our principal role is to represent Orion's pharmaceutical products in the UK across a range of therapy areas including Respiratory, Women’s Health and Neurological Disorders.
In the spirit of the values which are common to all units and employees of the Group, we endeavour to provide innovative medicinal treatments and best quality service to patients, healthcare professionals and the community in the UK, the region we operationally cover.
We are continuously developing new drugs and treatment methods. The core therapy areas of our pharmaceutical R&D are oncology and pain. We collaborate closely with healthcare professionals and leading global research institutions and pharmaceutical companies.
www.orionpharma.co.uk

July 2025/CORP-233(4)

As a global leader in allergy and autoimmune disease diagnostics, we are committed to providing accurate, clinically relevant testing solutions to aid in the proper disease diagnosis and patient management. With more than 550 whole allergens and allergen mixes, and 100 allergen components available our products are documented in more than 6,000 publications and referenced in multiple health guidelines. These may be some of the reasons for ImmunoCAP™ being acknowledged as the gold standard technology for specific IgE blood testing

TidalSense is an innovative respiratory diagnostics company based in Cambridge, UK. We have now launched N-Tidal™ Diagnose - a regulated, secure class 2a medical device diagnostic solution delivered as a service. It combines state of the art hardware (N-Tidal®) with AI-powered diagnostic software to deliver COPD diagnosis at the point of care within minutes.

Leveraging a revolutionary new patented sensor technology, N-Tidal® Diagnose performs real-time geometric analysis of CO2 breath waveforms to provide highly sensitive quantification of lung function, from relaxed breathing.